New Generation Vaccine Strategies against COVID-19

Abstract

Immunisation Schedule. Influenza A (H5N1) update: "Bird flu spillover to mammals needs to be monitored closely, risk to humans currently low but we must prepare". (WHO). Respiratory Syncytial Virus (RSV) Bivalent Subgroups A and B Vaccine for Infants and Adults (due 2023). False Listing of RB51 as Approved Medicine for Brucellosis or Malta Fever. Streptococcus pneumoniae PCV20. R21/Matrix-M™ Malaria (Plasmodium falciparum) vaccine 77% efficacy (due 2023). Bivalent SARS-Cov-2. [I am very thankful to receive links, additions and corrections to update, and to remove any obsolete material herein if spotted. Anti-Covid-19, anti-MMR, anti-Gardasil, anti-poliovirus anti-vaxxer depopulating messages are both unwelcome and repulsive to me.] BREAKING NEWS: Vaccine Catastrophe - Veterinary Vaccine (Live-Attenuated Brucella abortus strain RB51) has incorrectly been indicated as an 'approved' prophylactic therapy for human vaccination against Brucellosis or Malta Fever (also variously known as ‘Mediterranean Fever’ and ‘Undulant Fever’). This error is totally inexcusable as this strain is extremely harmful when given to humans. Immunisation Schedule for Zaire Ebola virus for work where large bull (bovine) and buffalo herds are present (put together for the rescue and care insurers). Zaire Ebola contamination management in large herds of aforesaid large ruminants proves problematic with the biohazard suit that protect from the disease vectors as the animals respond aggressively to the human protective gear leading to panicking animals attacks, attempts of human butchery and animal rummage where people and properties can suddenly become threatened, as a health protection gives rise to animal threat by the rummaging animals trampling and horn attacking people in biohazard gear. The ring fencing experimental Zaire Ebola vaccines were not available at the time of this original plan instigated where the China-based organisation prepared an emergency quantitative easing (QE) cash programme, ‘helicopter drops of money’ as a mitigation strategy to persuade the food producers and food vendors to continue serving the general public against an infection risk during a major ebola epidemic - to prevent food industry's distribution and production collapses as the personnel might otherwise decide to stop working and to stay home so as to avoid infecting themselves by the dangerous pathogen (in this case a Zaire Ebola Virus). The above can lead to severe food shortages and ultimately potential starvation occurrence unless that epidemic had not subsided soon enough to prevent this secondary consequence from emerging. Because of similarity of early Zaire Ebola symptoms to other infectious illnesses at the early stages, the work undertaken in remote areas, the lead time in medical evacuations in case of illnesses, and the immense cost of privately-funded flying hospital dispatch to carry out a rescue operation, an exhaustive mutual exclusion prophylactic scheme was initiated to minimise unnecessary calls for such a flying hospital facility (remote medical service) from overseas. Reported BEXSERO to GlaxoSmithKline on an unlisted side effect of stealthy temperature rise (see 19/03/2020 version, page 7) to +42.3C / +108.1F with weakening of normal body temperature control like sweating and relative lack of sense of highly elevated body temperature able to cause heat stroke and other related damage to body. The immunisation schedule incorporates emergency authorisation Covid-19 immunisations and coronavirus vaccines that shortly complete their approval. Some of the Covid-19 immunisations likely vanish from marketplace as soon as the pandemic is over whereas some other vaccine designs may seek themselves second life as generic coronavirus immunisations. (The research field of coronaviruses is rapidly changing with these overlooked viruses also causing many common colds is brought into spotlight.) Almost all Covid-19 products have not been tested for concomitant use with many other immunisation products and therefore a reasonable space should be allowed between immunisations to avoid adverse effect risks. Because of this one ought to consider whether at current pandemic situation some immunisation products of lesser importance should be taken and whether it is better to defer them until situation clears (considering the ongoing infections with Covid-19 variants and especially in some remote regions where sequencing of the variants is very sparse as the protection to Covid-19 is very important). Because of above reason, this schedule is not currently geared for rapid deployment in tropics as too many uncertainties lie within which good protection against Covid-19 must prevail. Section on Covid-19 products is continually expiring due to evolving situation. Updates on Streptococcus pneumoniae PCV20. The latest version of the document supersedes all earlier versions that ought to be discarded and not used.